Abstract:Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in the gene coding cardiac ryanodine receptor (RyR2) and is one of the most dangerous inherited arrhythmia disorders. While variable expressivity and penetrance have been described in CPVT, no genetic modifiers of disease have been identified. In other inherited disorders, the cumulative gene dosage effect, whereby ≥2 mutations influence the phenotype is a potential prognosticator. However, this phenomenon has not been described in CPVT. This is a study of patients enrolled in the Pediatric and Congenital Electrophysiology Society CPVT Registry with ≥2 variants. Population allele frequencies, literature review, the American College of Medical Genetics (ACMG) criteria, and mapping mutants onto a cryo-EM structure of RyR2 were used to determine pathogenicity. The 3D model of pig RyR2 in the open-state was used to predict structural impact of variants (figure). Among 237 subjects, 194 (82%) had genetic testing. Nine patients (5%) (median age 10 (IQR 7.5-12) years had ≥2 variants. Life-threatening events (cardiac arrest and/or syncope) occurred in seven subjects (78%). Ventricular tachycardia was documented in eight patients (89%), and treatment failure in 43%. No deaths occurred during follow-up (median 29 months; IQR 11-39). Two RYR2 variants affected eight patients (89%), and one patient had a heterozygous RYR2 variant and homozygous CASQ2 variants. By ACMG criteria, eight of 12 variants (67%) were pathogenic/likely pathogenic, while all others were variants of uncertain significance (VUS). Structural evaluation led to an upgrade from VUS to likely pathogenic for one variant, and a downgrade from VUS to likely benign for one variant. More than one variant may underlie a minority of CPVT cases. This observation poses challenges with respect to diagnosis and family counselling. While multiple variant carriers in the present study were usually severely affected, further research is needed to determine the significance and generalizability of this observation. The RyR2 homology model can be a useful tool when pathogenicity is unclear after applying contemporary variant classification scores.

Catecholaminergic polymorphic ventricular tachycardia: a paradigm to understand mechanisms of arrhythmias associated to impaired Ca2+ regulation

Characterization of a Novel Mutation in the Cardiac Ryanodine Receptor That Results in Catecholaminergic Polymorphic Ventricular Tachycardia

Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia

Inherited Dysfunction of Sarcoplasmic Reticulum Ca2+ Handling and Arrhythmogenesis

Clinical challenges in catecholaminergic polymorphic ventricular tachycardia

Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia: Recent Advances Toward Personalized Care

Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies

Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin

Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learnt from genetic diseases and transgenic mice

Impaired Binding to Junctophilin2 and Nanostructural Alteration in CPVT Mutation

Inherited calcium channelopathies in the pathophysiology of arrhythmias

Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia

The Clinical and Genetic Spectrum of Catecholaminergic Polymorphic Ventricular Tachycardia: Findings from an International Multicentre Registry

Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model

Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function

Location of ryanodine receptor type 2 mutation predicts age of onset of sudden death in catecholaminergic polymorphic ventricular tachycardia - A systematic review and meta-analysis of case-based literature

Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor

Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia

CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia

MULTIPLE GENETIC VARIANTS IN CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA: A CLINICAL AND MOLECULAR REPORT FROM THE PACES CPVT REGISTRY

Genetic Inhibition of Mitochondrial Permeability Transition Pore Exacerbates Ryanodine Receptor 2 Dysfunction in Arrhythmic Disease